Withholding interferon-alpha from patients with chronic myeloid leukaemia prior to bone marrow examination does not improve the chance of a successful cytogenetic analysis

Br J Haematol. 2004 Feb;124(4):559-60. doi: 10.1111/j.1365-2141.2004.04806.x.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Bone Marrow Cells / drug effects
  • Bone Marrow Examination / methods
  • Cytogenetic Analysis / methods*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Recombinant Proteins

Substances

  • Antineoplastic Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins